Feasibility of Identifying the Tobacco-related Global Metabolome in Blood by UPLC–QTOF-MS

Metabolomics is likely an ideal tool to assess tobacco smoke exposure and the impact of cigarette smoke on human exposure and health. To assess reproducibility and feasibility of this by UPLC–QTOF-MS, three experiments were designed for the assessment of smokers’ blood. Experiment I was an analysis of 8 smokers with 8 replicates. Experiment II was an analysis of 62 pooled quality control (QC) samples from 7 nonsmokers’ plasma placed as every tenth sample among a study of 613 samples from 160 smokers. Finally, to examine the feasibility of metabolomic study in assessing smoke exposure, Experiment III consisted of 9 smokers and 10 nonsmokers’ serum to evaluate differences in their global metabolome. There was minimal measurement and sample preparation variation in all experiments, although some caution is needed when analyzing specific parts of the chromatogram. When assessing QC samples in the large scale study, QC clustering indicated high stability, reproducibility, and consistency. Finally, in addition to the identification of nicotine metabolites as expected, there was a characteristic profile distinguishing smokers from nonsmokers. Metabolites selected from putative identifications were verified by MS/MS, showing the potential to identify metabolic phenotypes and new metabolites relating to cigarette smoke exposure and toxicity.

[1]  J. Schwender,et al.  Metabolic cartography: experimental quantification of metabolic fluxes from isotopic labelling studies. , 2012, Journal of experimental botany.

[2]  Y. Oda,et al.  Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology[S] , 2012, Journal of Lipid Research.

[3]  H. Ressom,et al.  LC-MS-based metabolomics. , 2012, Molecular bioSystems.

[4]  J. W. Allwood,et al.  Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. , 2011, Analytical chemistry.

[5]  Florian Kronenberg,et al.  Differences between Human Plasma and Serum Metabolite Profiles , 2011, PloS one.

[6]  H. Ashrafian,et al.  Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. , 2011, Trends in microbiology.

[7]  R. Krishnan,et al.  Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept , 2011, Translational Psychiatry.

[8]  B. McManus,et al.  The Human Serum Metabolome , 2011, PloS one.

[9]  Tobin J Dickerson,et al.  Characterization of differences between blood sample matrices in untargeted metabolomics. , 2011, Analytical chemistry.

[10]  Oliver F Bathe,et al.  Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[11]  C. Barbas,et al.  Metabolomic approach with LC-MS reveals significant effect of pressure on diver's plasma. , 2010, Journal of proteome research.

[12]  E. Want,et al.  Global metabolic profiling procedures for urine using UPLC–MS , 2010, Nature Protocols.

[13]  P. Shields,et al.  Evaluation of In vitro Assays for Assessing the Toxicity of Cigarette Smoke and Smokeless Tobacco , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[14]  Brett R. Wenner,et al.  Metabolomics Applied to Diabetes Research , 2009, Diabetes.

[15]  A. Smilde,et al.  Characterizing the precision of mass-spectrometry-based metabolic profiling platforms. , 2009, The Analyst.

[16]  W. R. Wikoff,et al.  Variability analysis of human plasma and cerebral spinal fluid reveals statistical significance of changes in mass spectrometry-based metabolomics data. , 2009, Analytical chemistry.

[17]  David S. Wishart,et al.  MetaboAnalyst: a web server for metabolomic data analysis and interpretation , 2009, Nucleic Acids Res..

[18]  Olga Vitek,et al.  Statistical design of quantitative mass spectrometry-based proteomic experiments. , 2009, Journal of proteome research.

[19]  U. Ceglarek,et al.  Challenges and developments in tandem mass spectrometry based clinical metabolomics , 2009, Molecular and Cellular Endocrinology.

[20]  W. R. Wikoff,et al.  Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.

[21]  Joshua D. Knowles,et al.  Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. , 2009, Analytical chemistry.

[22]  S. Eckhardt,et al.  Clinical Applications of Metabolomics in Oncology: A Review , 2009, Clinical Cancer Research.

[23]  Steffen Neumann,et al.  Critical assessment of alignment procedures for LC-MS proteomics and metabolomics measurements , 2008, BMC Bioinformatics.

[24]  I. Wilson,et al.  Evaluation of the repeatability of ultra-performance liquid chromatography-TOF-MS for global metabolic profiling of human urine samples. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  M. Klapa,et al.  Standardizing GC-MS metabolomics. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[26]  Stephen J. Bruce,et al.  Global metabolic profiling analysis on human urine by UPLC-TOFMS: issues and method validation in nutritional metabolomics. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[27]  R. Gerszten,et al.  Application of metabolomics to cardiovascular biomarker and pathway discovery. , 2008, Journal of the American College of Cardiology.

[28]  John L Markley,et al.  Metabolite identification via the Madison Metabolomics Consortium Database , 2008, Nature Biotechnology.

[29]  R. Weinshilboum,et al.  Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.

[30]  David S Wishart,et al.  Human Metabolome Database: completing the 'human parts list'. , 2007, Pharmacogenomics.

[31]  I. Wilson,et al.  Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. , 2007, Journal of proteome research.

[32]  C. Lerman,et al.  New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. , 2007, Drug and alcohol dependence.

[33]  J. Idle,et al.  LC-MS-Based Metabolomics in Drug Metabolism , 2007, Drug metabolism reviews.

[34]  D. Hatsukami,et al.  Erratum: Biomarkers to assess the utility of potential reduced exposure tobacco products (Nicotine and Tobacco Research vol. 8 (2) (169-191)) , 2006 .

[35]  D. Hatsukami,et al.  Biomarkers to assess the utility of potential reduced exposure tobacco products. , 2006, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[36]  D. Lewis,et al.  Metabolism of coumarin by human P450s: a molecular modelling study. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[37]  J. Griffin.  The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.

[38]  R. Abagyan,et al.  XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. , 2006, Analytical chemistry.

[39]  A. Fernie,et al.  Metabolite profiling: from diagnostics to systems biology , 2004, Nature Reviews Molecular Cell Biology.

[40]  N. Benowitz,et al.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.

[41]  E. Dybing,et al.  Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke , 2003, Tobacco control.

[42]  Stephen S. Hecht,et al.  Tobacco carcinogens, their biomarkers and tobacco-induced cancer , 2003, Nature Reviews Cancer.

[43]  I. Wilson,et al.  Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.

[44]  C. Hansch,et al.  IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[45]  C. Lerman,et al.  Elucidating the role of genetic factors in smoking behavior and nicotine dependence , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[46]  R. Carleton,et al.  Are there gender differences in self-reported smoking practices? Correlation with thiocyanate and cotinine levels in smokers and nonsmokers from the Pawtucket Heart Health Program. , 2002, Journal of women's health.

[47]  G. Giovino,et al.  Reducing tobacco harm: research challenges and issues. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[48]  N. Reo.  NMR-BASED METABOLOMICS , 2002, Drug and chemical toxicology.

[49]  Disease Prevention.  Clearing the Smoke : Assessing the Science Base for Tobacco Harm Reduction , 2001 .

[50]  D. Hoffmann,et al.  The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. , 2001, Chemical research in toxicology.

[51]  S. Hecht,et al.  2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Hecht,et al.  Tobacco smoke carcinogens and lung cancer. , 1999, Journal of the National Cancer Institute.

[53]  R. Tyndale,et al.  A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.

[54]  Y. Funae,et al.  Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[55]  J. Jagadeesh,et al.  Menthol and nonmenthol cigarettes and smoke exposure in black and white women , 1996, Pharmacology Biochemistry and Behavior.

[56]  W. S. Caldwell,et al.  Intragastric Nitrosation of Nicotine Is Not a Significant Contributor to Nitrosamine Exposure , 1993, Annals of the New York Academy of Sciences.

[57]  D. Topping,et al.  Smoking and health , 1984, The Medical journal of Australia.

[58]  Hans V. Westerhoff,et al.  Methods in Systems Biology , 2011 .

[59]  Office on Smoking.  How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General , 2010 .

[60]  N. Serkova,et al.  Metabolomics of cancer. , 2009, Methods in molecular biology.

[61]  B. Hammock,et al.  Mass spectrometry-based metabolomics. , 2007, Mass spectrometry reviews.

[62]  Wolfram Weckwerth,et al.  Metabolomics : methods and protocols , 2007 .

[63]  WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 2005 .

[64]  X Yu,et al.  J.Chromatogr., B: Anal. Technol. Biomed. Life Sci. , 2004 .

[65]  R. Wallace,et al.  COMMITTEE TO ASSESS THE SCIENCE BASE FOR TOBACCO HARM REDUCTION , 2001 .

[66]  B. Mehić.  [Nicotine addiction]. , 2001, Medicinski arhiv.

[67]  D. Bleyl,et al.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs vol. 1 to 42. Supplement 7. 440 Seiten. International Agency for Research on Cancer, Lyon 1987. Preis: 65, – s.Fr , 1989 .

[68]  T. Lombardo,et al.  Relationship of type A behavior pattern in smokers to carbon monoxide exposure and smoking topography. , 1987, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[69]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[70]  E. Wada,et al.  Degradation of Nicotine by Soil Bacteria1 , 1954 .